Role of thermogenic adipose tissue in lipid metabolism and atherosclerotic cardiovascular disease: lessons from studies in mice and humans.

106 Clinical studies in subjects with type 2 diabetes showed that administration of an FGF21 analogue remarkably improved dyslipidaemia, including decreases in plasma LDL-cholesterol and triglycerides and an increase in HDL-cholesterol, while the much-anticipated glucose-lowering effect did not reach statistical significance. 107 , 108 These lipid-manipulating effects of FGF21 treatment in humans suggest that FGF21-based therapies may be effective to combat human dyslipidaemia and atherosclerotic CVD, as shown in our preclinical study. 103 Whether and to what extent BAT plays a role in the beneficial effects of FGF21 in humans still remains to be investigated.

also in 111,027 other papers